JPRN-UMIN000006931已完成4 期
The efficacy and safety of the antiplatelet therapy in acute non-cardiogenic ischemic stroke. - The efficacy and safety of the antiplatelet therapy in acute non-cardiogenic ischemic stroke.
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba0 个研究点目标入组 130 人开始时间: 2011年12月22日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Having aphasia or mental retardation. 2) Having serious liver dysfunction, renal dysfunction, angina, myocardial infarction. 3) Having hemorrhagic disease. 4) Having tachyarrhythmia to need treatment. 5) A patient with suspected cardiogenic cerebral infarction. 6) Contraindication for cilostazol, aspirin, ozagrel, and edaravon.
研究者
相似试验
招募中
不适用
Effect and safety of tailored antiplatelet therapy based on platelet function testing in coil embolization for unruptured aneurysmKCT0005550Bundang Jesaeng Hospital1,780
尚未招募
Unknown
An observation study to evaluate safety and efficacy of antiplatelet drugs in patients after percutaneous coronary intervention.CTRI/2023/10/059339Pragya Hangma Subba
尚未招募
不适用
A clinical trial to study effects of clopidogrel and newer antiplatelet agents ( Ticagrelor and Prasugrel) in patients with acute coronary syndrome who underwent PCI.CTRI/2021/12/038560N Mehta institute of cardiology and research center
已完成
不适用
Evaluation of the safety and efficacy of platelet rich plasma in treatment of patients with chronic telogen effluviumSkin and Connective Tissue DiseasesPACTR202006539654415Faculty of Medicine Sohag University30
进行中（未招募）
1 期
A study designed to evaluate a modified Anti-Platelet Therapy (drugs that prevent blood platelets from clotting) after implantation of a Firehawk drug-eluting stent (metallic tube, which is covered with a drug and inserted into stenosed blood vessels of the heart in order to keep them open) in patients who have experienced a heart attack and were treated with complete revascularisatioEUCTR2020-005933-34-NLSorin CRM SAS (Microport CRM)2,246